Stock listing

NYSE:ANRO Alto Neuroscience, Inc. Stock

Home listing (NYSE) of Alto Neuroscience, Inc.

Follow Alto Neuroscience, Inc. into a list and get an email when it puts out news.

Share price · NYSE:ANRO

$25.37 USD -0.54 (-2.1%)

Close on Nov 20, 2026

Past year +79.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$24.40 – $26.48 USDNov 20, 2026
Volume
522,526 sharesNov 20, 2026
Market cap
$1.02B USDAt the close on Nov 20, 2026 · price × 40.11M shares outstanding
52-week range
$12.51 – $37.48 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$16.68M USDMedian day 522,526 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Alto Neuroscience, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:ANRO · Home$25.37 USD-0.54 (-2.1%)522,526$25.76$26.48$24.40$25.91Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ANRO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$25.37-0.54-2.1%$25.76$26.48$24.40522,526
$25.91+1.00+4.0%$24.99$27.75$24.95986,150
$24.91-2.21-8.1%$27.10$27.12$24.79498,655
$27.12-2.42-8.2%$29.13$29.54$26.95789,240
$29.54-1.08-3.5%$30.01$30.76$28.54610,910
$30.62-0.53-1.7%$30.44$33.46$30.351,288,381
$31.15+2.54+8.9%$29.75$31.30$28.881,221,856
$28.61+0.81+2.9%$27.55$28.84$27.05515,790
$27.80+2.64+10.5%$25.82$29.56$25.02824,850
$25.16+3.29+15.0%$22.12$25.42$21.96616,285
$21.87-1.43-6.1%$23.06$23.51$21.85411,271
$23.30+0.60+2.6%$23.65$23.65$22.33449,157
$22.70+0.51+2.3%$22.71$23.14$22.40505,158
$22.19-0.41-1.8%$22.80$23.18$21.50473,275
$22.60-0.87-3.7%$23.21$23.21$21.90484,403
$23.47+0.14+0.6%$23.46$24.15$23.01388,831
$23.33+0.14+0.6%$22.86$23.47$22.34300,195
$23.19+1.08+4.9%$22.22$23.35$21.92469,250
$22.11+0.14+0.6%$22.17$22.26$21.70550,061
$21.97-0.23-1.0%$21.95$22.45$21.45379,246
$22.20-1.12-4.8%$22.70$24.29$22.18510,817
$23.32-1.09-4.5%$24.74$25.01$23.28663,459
$24.41+1.59+7.0%$23.23$24.91$23.02869,407
$22.82+0.88+4.0%$22.36$23.40$22.01681,860
$21.94-0.68-3.0%$21.97$22.63$21.71648,300
$22.62+0.91+4.2%$21.92$23.31$21.62529,900
$21.71-0.38-1.7%$21.83$22.59$21.322,280,100
$22.09-2.06-8.5%$24.04$24.20$22.07661,800
$24.15-0.22-0.9%$24.34$25.25$23.86390,300
$24.37+0.34+1.4%$24.00$25.11$23.81649,400
$24.03+0.51+2.2%$23.03$24.05$22.81409,800
$23.52-0.17-0.7%$23.39$24.42$23.33347,900
$23.69-0.32-1.3%$24.06$24.70$23.50576,300
$24.01-0.79-3.2%$24.63$25.85$23.80550,300
$24.80-0.51-2.0%$25.64$26.10$23.87660,700
$25.31-0.22-0.9%$25.50$26.49$25.12575,800
$25.53-1.05-4.0%$26.87$27.41$25.53891,600
$26.58-0.08-0.3%$26.44$27.42$25.75763,400
$26.66+0.17+0.6%$26.36$27.76$25.89587,000
$26.49-0.69-2.5%$27.36$27.62$26.48366,300
$27.18-0.32-1.2%$27.51$27.91$26.39788,400
$27.50-3.28-10.7%$30.39$30.62$26.41639,900
$30.78+0.15+0.5%$30.71$31.46$30.18347,100
$30.63+0.36+1.2%$30.64$30.81$29.80357,800
$30.27-0.71-2.3%$31.32$31.65$30.082,199,200
$30.98+0.98+3.3%$30.59$31.65$30.11411,000
$30.00-0.25-0.8%$30.50$31.21$29.87548,400
$30.25-1.43-4.5%$31.40$31.40$29.95420,400
$31.68-0.32-1.0%$31.96$32.99$31.16453,300
$32.00+0.32+1.0%$32.00$33.13$31.11415,700
$31.68-2.39-7.0%$33.71$34.20$31.35790,000
$34.07-1.74-4.9%$35.48$36.91$33.91556,800
$35.81+0.26+0.7%$34.69$36.84$34.08580,900
$35.55-0.85-2.3%$36.18$36.98$35.45269,900
$36.40-0.24-0.7%$36.84$37.36$35.91324,700
$36.64+1.44+4.1%$35.97$37.39$35.22432,800
$35.20-0.18-0.5%$35.20$36.04$34.62350,100
$35.38+0.25+0.7%$34.89$35.83$33.98764,100
$35.13-1.17-3.2%$35.00$35.72$34.73246,700
$36.30-0.23-0.6%$36.08$36.82$35.46359,600
$36.53+0.22+0.6%$35.80$36.86$34.87282,800
$36.31+0.06+0.2%$36.52$37.48$35.74474,000
$36.25+1.97+5.7%$33.96$36.99$33.52867,900
$34.28+0.03+0.1%$34.44$35.29$33.66291,100
$34.25-0.64-1.8%$34.36$34.65$33.65313,900
Ticker
NYSE:ANRO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE
Currency
USD

What changed lately

Latest news

All Alto Neuroscience, Inc. news

Alto Neuroscience, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 41 in all · newest Nov 10, 2026 · oldest 2025
Decks
3 decks · latest January 2026

Where Alto Neuroscience, Inc. is listed

ListingExchangeCountryCurrency
NYSE:ANRO · Home listing · This pageNYSEUnited StatesUSD
BOATS:ANROBOATSUnited StatesUSD

Valuation

Price/book 3.4× against a median of 4.7×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$711.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.65

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alto Neuroscience, Inc. · NYSE:ANROUS$1.02BUS$711.7Mn/an/an/a3.4×n/a0.1×1.65
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$987.0Mn/a9.2×n/a9.5×−146.4%2.9×n/a
SpyGlass Pharma, Inc. · NASDAQ:SGPUS$1.02BUS$809.5Mn/an/an/a4.8×n/a0.0×1.01
Inhibrx Biosciences, Inc. · NASDAQ:INBXUS$1.02BUS$1.09Bn/a546×n/an/an/an/a1.89
Duality Biotherapeutics, Inc. · HKEX:9606US$992.3MUS$608.2Mn/a4.8×n/a4.6×−170.8%0.3×n/a
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.6MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.4MUS$711.6M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Peptron, Inc. · KRX:087010US$979.6MUS$942.6Mn/a211×n/a10.2×−342.2%0.2×n/a
Median of the othersUS$1.00BUS$931.4M10.4×9.4×95.7×4.7×−137.6%0.2×1.46

Forecasts

10 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
38.67 USD · Analysts' mean
EPS, year to Dec 2026
-2.48 · 2 analysts

Team and board

Officers

OfficerRole
Amit EtkinFounder, President, and Chief Executive Officer
Nick SmithPresident and Chief Financial Officer
Michael HanleyChief Operating Officer
Erin R. McQuadeGeneral Counsel and Chief Administrative Officer
Adam SavitzChief Medical Officer
Jessica PowellChief Development Officer

Board

DirectorRole
Amit EtkinFounder, President, and Chief Executive Officer
Andrew DreyfusBoard Member
Andrew MillerBoard Member
Christopher Nixon CoxBoard Member
Gwill YorkBoard Member
Husseini ManjiBoard Member
Raymond SanchezBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+8.9%
Q2 2026Aug 12, 2026 · After close+10.7%
Q1 2026May 13, 2026 · Before open−7.2%
Q4 2025Mar 20, 2026−9.2%
Q3 2025Nov 12, 2025 · Before open+6.0%
Q2 2025Aug 13, 2025 · After close−0.3%
Q1 2025May 14, 2025 · After close+10.4%
Q4 2024Mar 20, 2025−5.4%
Q3 2024Nov 12, 2024 · After close+0.7%
Q2 2024Aug 13, 2024 · After close+6.0%
All 12 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close−2.3%
Q4 2023Mar 21, 2024 · After close+5.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck70 slidesJanuary 2026
TD Cowen 45th Annual Health Care Conference (March 2025)Conference17 slidesMar 4, 2025
Investor Day (September 2024)Investor day74 slidesSep 9, 2024

Open Decks

Financings

RaiseDate
Registered direct offering of common stock
Announced: about US$100M · US$26.48 a share · BofA Securities +4
Dealers: BofA Securities (co-lead), Stifel (co-lead), William Blair (co-lead), Baird (co-lead), Jones
Buyers: EcoR1 Capital
Use of proceeds: Accelerate and expand clinical development of ALTO-207, including an additional Phase 3 trial in treatment-resistant depression, and working capital
Jul 13, 2026
Private placement of private placement financing (PIPE)
Closed: US$50M raised · US$5.914 a share
Buyers: Perceptive Advisors (Led the financing); Commodore Capital; Vestal Point Capital; Vivo Capital
Use of proceeds: To support the accelerated development of ALTO-207 following the successful FDA meeting
Nov 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Feb 1, 2024.

Price
US$16.00 a share
Shares offered
8,040,000 shares of common stock
Offering size
US$128.6 million
Underwriters' option
Up to 1,206,000 more shares
Underwriters
Jefferies, TD Cowen, Stifel, William Blair, Baird · In the order on the cover
Shares delivered
On or about Feb 6, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceNov 22, 2023
Filed publiclyJan 12, 2024
Amended twiceNewest Jan 29, 2024
Shares registered with an exchangeJan 30, 2024
Declared effective by the SECFeb 1, 2024
Final prospectus, with the priceFeb 5, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Revenue0000210.0K
Cost of revenue661.0K502.0K373.0K342.0K145.0K
Gross profit-661.0K-502.0K-373.0K-342.0K65.0K
Research and development45.6M45.6M47.0M47.0M30.3M30.3M23.7M8.37M
Selling, general and administrative20.7M21.6M7.52M5.50M3.90M
Operating income-66.4M-66.4M-68.6M-68.6M-37.8M-37.8M-29.2M-12.1M
Depreciation and amortization661.0K661.0K502.0K502.0K373.0K373.0K342.0K145.0K
EBITDA-65.7M-65.7M-68.1M-68.1M-37.4M-37.4M-28.9M-11.9M
Interest expense2.47M2.47M1.38M1.38M1.37M1.37M0
Income before tax-63.2M-61.4M-36.3M-27.7M-9.19M
Income tax00-61.4M0
Net income-63.2M-63.2M-61.4M-61.4M-36.3M-36.3M-27.7M-9.19M
Earnings per share, basic-2.19-2.19-2.50-2.50-9.73-1.35-1.08-0.36
Earnings per share, diluted-2.19-2.50-9.73

Balance sheet

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash and equivalents176.5M176.5M168.2M168.2M82.5M82.5M48.3M25.7M
Receivables8.00K546.0K1.74M
Inventory0
Current assets177.7M177.7M169.3M169.3M85.4M85.4M49.2M27.7M
Property, plant and equipment1.87M2.67M1.11M
Total assets184.7M184.7M177.5M177.5M86.6M86.6M50.9M28.8M
Accounts payable1.88M1.88M1.58M1.58M1.07M1.07M1.61M600.0K
Current liabilities11.3M11.3M10.0M10.0M5.61M5.61M5.56M1.81M
Long-term debt16.2M18.4M10.3M11.6M9.86M9.86M9.46M
Total debt16.8M4.41M10.3M16.9M9.86M9.99M82.1M38.2M
Total liabilities33.5M33.5M26.1M26.1M16.8M158.3M89.3M41.3M
Shareholders' equity151.1M151.1M151.5M151.5M-71.7M-71.7M-38.4M-12.5M
Shares outstanding31.9M28.9M27.0M24.6M3.83M26.9M25.6M25.6M

Cash flow

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash from operations-51.8M-51.8M-47.4M-47.4M-33.4M-33.4M-20.4M-9.26M
Capital spending-24.0K-24.0K-2.08M-2.08M-470.0K-470.0K-732.0K-680.0K
Free cash flow-51.8M-51.8M-49.5M-49.5M-33.9M-33.9M-21.1M-9.94M
Cash from investing-24.0K-24.0K-2.08M-2.08M-470.0K-470.0K-732.0K-680.0K
Cash from financing60.1M60.1M135.7M135.7M68.1M68.1M43.8M31.7M
Share buybacks-167.0K0
Change in cash8.26M8.26M86.2M86.2M34.2M34.2M22.6M21.7M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
144 · Notice of proposed saleSep 29, 2026Other filingsSEC
8-K · Current reportAug 27, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
All 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 20, 2026Big-stake noticeSEC
8-K · Current reportJul 14, 2026Material contractSEC
424B5 · ProspectusJul 14, 2026Offer documentSEC
8-K · Current reportJul 13, 2026ResultsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 29, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Management or board changeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
8-K · Current reportMay 13, 2026Management or board changeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveApr 21, 2026Other filingsSEC
CORRESP · Letter to the SECApr 17, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 16, 2026Other filingsSEC
S-3 · Registration statementApr 10, 2026Offer documentSEC
8-K · Current reportApr 1, 2026Current reportSEC
ARS · Annual report to shareholdersMar 26, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 26, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 26, 2026Meeting noticeSEC
8-K · Current reportMar 16, 2026Material contractSEC
S-8 · Registration statement for employee plansMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 11, 2025Other filingsSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
S-3 · Registration statementNov 26, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
DOct 27, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2025Big-stake noticeSEC
8-K · Current reportOct 20, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeOct 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2025Insider tradeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
8-K · Current reportJul 8, 2025Management or board changeSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 3, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
DEFR14AMay 9, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 1, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 1, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 1, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportFeb 12, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 12, 2025Other filingsSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
CORRESP · Letter to the SECFeb 7, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 7, 2025Other filingsSEC
8-K · Current reportFeb 3, 2025ResultsSEC
S-3 · Registration statementFeb 3, 2025Offer documentSEC
8-K · Current reportJan 16, 2025Material contractSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportOct 22, 2024Current reportSEC
SC 13G · Big-stake noticeOct 21, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportJul 29, 2024Material contractSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2024Insider tradeSEC
8-K · Current reportMay 21, 2024Management or board changeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
SC 13G · Big-stake noticeMar 29, 2024Big-stake noticeSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2024Insider tradeSEC
8-K · Current reportMar 11, 2024Management or board changeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 8, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 7, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 6, 2024Offer documentSEC
8-K · Current reportFeb 6, 2024Current reportSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
424B4 · ProspectusFeb 5, 2024Offer documentSEC
3 · Initial statement of ownershipFeb 2, 2024Insider tradeSEC
SEC STAFF LETTERFeb 2, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2024Other filingsSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringFeb 1, 2024Offer documentSEC
CERT · Exchange's certificate of listingJan 30, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJan 30, 2024Other filingsSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 29, 2024Offer documentSEC
S-1/A · Registration statement, amendedJan 29, 2024Offer documentSEC
CORRESP · Letter to the SECJan 25, 2024Other filingsSEC
CORRESP · Letter to the SECJan 24, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 19, 2024Other filingsSEC
CORRESP · Letter to the SECJan 12, 2024Other filingsSEC
S-1 · Registration statementJan 12, 2024Offer documentSEC
SEC STAFF LETTERJan 10, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 9, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftDec 28, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedDec 28, 2023Offer documentSEC
UPLOAD · Letter from the SECDec 19, 2023Other filingsSEC
DNov 27, 2023Other filingsSEC
DNov 27, 2023Other filingsSEC
DNov 27, 2023Other filingsSEC
DNov 27, 2023Other filingsSEC
DRS · Draft registration statementNov 22, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Alto Neuroscience, Inc.’s releases · as of Nov 5, 2026

Common shares
40,110,620
Fully diluted
40,110,620

Fully diluted

LineSharesAs of
Common shares40,110,620Nov 5, 2026

Share count over time

CountShares
Nov 5, 202640,110,620

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Alpha Wave Global, LP3.71M9.2%US$94.7MNo changeNov 13, 2026
BlackRock2.73M6.8%US$69.6M+605KNov 13, 2026
Commodore Capital LP2.72M6.8%US$69.5MNo changeNov 16, 2026
Vanguard2.3M5.7%US$58.6M+492KNov 16, 2026
EcoR1 Capital, LLC2.23M5.6%US$57MNewNov 16, 2026
Perceptive Advisors LLC1.76M4.4%US$45M+151KNov 16, 2026
Adage Capital Partners Gp, L.L.C.1.7M4.2%US$43.4M+102KNov 16, 2026
Spruce Street Capital LP1.68M4.2%US$42.8M+324KNov 13, 2026
Vivo Capital, LLC1.36M3.4%US$34.7M+151KNov 13, 2026
T. Rowe Price1.28M3.2%US$32.8M+926KNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Driehaus Capital Management LLC1.23M3.1%US$31.5M+744KNov 16, 2026
Bellevue Group AG1.16M2.9%US$29.7MNewNov 16, 2026
Franklin Templeton993K2.5%US$23.1M−19,822Nov 12, 2026
Parkman Healthcare Partners LLC949K2.4%US$24.2M+520KNov 16, 2026
State Street946K2.4%US$24.2M+260KNov 12, 2026
Marshall Wace, LLP859K2.1%US$21.9M+634KNov 13, 2026
Geode Capital832K2.1%US$21.3M+154KNov 6, 2026
Northern Trust693K1.7%US$17.7M+60,456Nov 16, 2026
72 Investment Holdings, LLC668K1.7%US$17MNo changeNov 16, 2026
Affinity Asset Advisors, LLC643K1.6%US$16.4M−207KNov 13, 2026
Point72 Asset Management, L.P.576K1.4%US$14.7M+73,425Nov 16, 2026
Saturn V Capital Management LP518K1.3%US$13.2M+335KNov 16, 2026
Bank of America511K1.3%US$13M+492KNov 16, 2026
Armistice Capital, LLC500K1.2%US$12.8M−364KNov 16, 2026
Venrock Adviser, LLC500K1.2%US$12.8MNo changeNov 16, 2026
Integral Health Asset Management, LLC500K1.2%US$12.8MNo changeNov 16, 2026
Ikarian Capital, LLC482K1.2%US$12.3M+75,000Nov 16, 2026
Eventide Asset Management, LLC425K1.1%US$10.9MNewNov 13, 2026
Goldman Sachs405K1.0%US$10.3M+168KNov 16, 2026
Ameriprise361K0.90%US$9.22M+170KNov 16, 2026
Invesco354K0.88%US$9.03M+339KNov 12, 2026
Schwab333K0.83%US$8.49M+252KNov 16, 2026
Morgan Stanley261K0.65%US$6.66M+186KNov 13, 2026
Schonfeld Strategic Advisors LLC209K0.52%US$5.32M−49,090Nov 16, 2026
Fidelity151K0.38%US$3.85M+144KNov 10, 2026
Eversept Partners, LP128K0.32%US$3.26M−505Nov 16, 2026
Boothbay Fund Management, LLC128K0.32%US$3.26M+21,390Nov 16, 2026
Alkeon Capital Management LLC102K0.25%US$2.61MNo changeNov 13, 2026
Two Sigma102K0.25%US$2.6M−45,420Nov 16, 2026
BNY92,7980.23%US$2.37M+16,468Nov 5, 2026
Wellington91,7210.23%US$2.34M+20,808Nov 16, 2026
TD87,1020.22%US$2.32M+43,302Nov 13, 2026
Susquehanna83,4700.21%US$2.13M+75,472Nov 16, 2026
XTX Topco Ltd82,4450.21%US$2.1M+35,844Nov 16, 2026
AdvisorShares Investments LLC81,6220.20%US$2.08M+10,874Nov 9, 2026
Stifel Financial Corp79,4520.20%US$2.03M−6,028Nov 12, 2026
Dimensional78,2920.20%US$2M+35,731Nov 4, 2026
UBS78,1190.19%US$1.99M+19,422Nov 16, 2026
Squarepoint Ops LLC76,4560.19%US$1.95M+55,170Nov 9, 2026
AWM Investment Company, Inc.70,0000.17%US$1.79M−10,000Nov 13, 2026

This page holds 50 of 126 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund1.01M2.5%US$26.7M+136KJun 30, 2026
iShares Russell 2000 ETF663K1.7%US$17.5MNewJun 30, 2026
Franklin Biotechnology Discovery Fund348K0.87%US$9.42M−57,371Jul 31, 2026
Vanguard Extended Market Index Fund347K0.86%US$9.15M+44,295Jun 30, 2026
Fidelity Small Cap Index Fund287K0.72%US$7.77MNewJul 31, 2026
iShares Russell 2000 Growth ETF240K0.60%US$6.34MNewJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.228K0.57%US$6.02M−40,223Jun 30, 2026
iShares Biotechnology ETF222K0.55%US$5.85M+8,836Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF190K0.47%US$5.02M+117KJun 30, 2026
Fidelity Extended Market Index Fund138K0.34%US$2.77M−1,925May 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Micro-Cap ETF88,0480.22%US$2.32M+29,504Jun 30, 2026
AdvisorShares Psychedelics ETF70,7480.18%US$1.87M+29,725Jun 30, 2026
Schwab Small-Cap Index Fund63,5700.16%US$1.72MNewJul 31, 2026
Master Small Cap Index Series48,9590.12%US$1.29MNewJun 30, 2026
Fidelity Total Market Index Fund48,6670.12%US$977KNo changeMay 31, 2026
Fidelity Series Total Market Index Fund40,6850.10%US$817K+1,984May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF37,4540.09%US$988K+816Jun 30, 2026
Nuveen Small Cap Blend Index Fund34,6830.09%US$939KNewJul 31, 2026
ALPS Medical Breakthroughs ETF32,0250.08%US$643K+4,337May 31, 2026
EQ/2000 Managed Volatility Portfolio28,2390.07%US$745KNewJun 30, 2026
Ultra-Small Company Market Fund25,0000.06%US$660KNo changeJun 30, 2026
Fidelity Small Cap Growth Index Fund24,5380.06%US$648KNewJun 30, 2026
Ultra-Small Company Fund23,5530.06%US$622KNo changeJun 30, 2026
Nuveen Equity Index Fund21,4500.05%US$581KNewJul 31, 2026
LVIP State Street Small-Cap Index Fund18,8000.05%US$496KNewJun 30, 2026
Schwab Total Stock Market Index Fund16,4170.04%US$444KNo changeJul 31, 2026
T. Rowe Price Health Sciences Portfolio16,4000.04%US$433KNo changeJun 30, 2026
Vanguard Balanced Index Fund15,8740.04%US$419KNo changeJun 30, 2026
EQ/Small Company Index Portfolio15,5000.04%US$409KNewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund15,2000.04%US$401K+2,329Jun 30, 2026
U.S. Micro Cap Portfolio15,1470.04%US$410K+12,873Jul 31, 2026
Virtus Biotech Clinical Trials Etf14,4760.04%US$392KNewJul 31, 2026
Small Cap Index Fund13,2060.03%US$349KNewJun 30, 2026
U.S. Small Cap Portfolio12,4830.03%US$338KNo changeJul 31, 2026
Global X Russell 2000 ETF12,4790.03%US$338KNewJul 31, 2026
T. Rowe Price Extended Equity Market Index Fund12,0460.03%US$318KNo changeJun 30, 2026
Avantis U.S. Small Cap Equity ETF11,2710.03%US$226K+1,055May 31, 2026
U.S. Core Equity 2 Portfolio10,9170.03%US$296KNo changeJul 31, 2026
EQ/AB Small Cap Growth Portfolio9,4000.02%US$248KNewJun 30, 2026
MetLife Russell 2000 Index Portfolio8,8680.02%US$234KNewJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio8,5000.02%US$224KNewJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund8,3360.02%US$226KNewJul 31, 2026
ATM Small Cap Managed Volatility Portfolio8,2090.02%US$217KNewJun 30, 2026
iShares Russell 3000 ETF7,5480.02%US$199KNewJun 30, 2026
Small-Cap Index Portfolio7,4770.02%US$197KNewJun 30, 2026
Direxion Daily Pharmaceutical & Medical Bull 3X Shares6,8330.02%US$185K+4,690Jul 31, 2026
Small Cap Core Fund6,4680.02%US$171K−277Jun 30, 2026
Health Sciences Trust5,9000.01%US$156KNo changeJun 30, 2026
1290 VT Micro Cap Portfolio5,8780.01%US$155K+1,758Jun 30, 2026
NVIT Small Cap Index Fund5,8100.01%US$153KNewJun 30, 2026

This page holds 50 of 104 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Hanley Jr. Michael Conick
Officer: CHIEF OPERATING OFFICER
Sale2,896USD 26.48US$76,686Nov 18, 2026
Hanley Jr. Michael Conick
Officer: CHIEF OPERATING OFFICER
Sale2,104USD 26.82US$56,421Nov 17, 2026
Hanley Jr. Michael Conick
Officer: CHIEF OPERATING OFFICER
Sale56,410USD 27.46US$1.55MNov 16, 2026
Hanley Jr. Michael Conick
Officer: CHIEF OPERATING OFFICER
Sale10,895USD 28.43US$310KNov 16, 2026
Hanley Jr. Michael Conick
Officer: CHIEF OPERATING OFFICER
Sale2,695USD 29.09US$78,388Nov 16, 2026
Smith Nicholas Conrad
Officer: PRESIDENT AND CFO
Sale23,170USD 25.78US$597KSep 30, 2026
Smith Nicholas Conrad
Officer: PRESIDENT AND CFO
Sale886USD 26.87US$23,807Sep 30, 2026
Smith Nicholas Conrad
Officer: PRESIDENT AND CFO
Sale110,830USD 26.58US$2.95MSep 29, 2026

Big stakes

HolderStakeSharesDate
Perceptive Advisors LLC9.99%4.18MJun 30, 2026
Commodore Capital LP9.90%3.59MMar 31, 2026
Sirenia Capital Management LP6.20%2.22MJun 30, 2026
BlackRock, Inc.6.00%2.1MJun 30, 2026
EcoR1 Capital, LLC5.80%2.23MJul 13, 2026
Vanguard Capital Management LLC5.02%1.97MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Miller
Other companies: Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 24, 2026); Karuna Therapeutics Inc (President of R&D · Jun 27, 2019 – Mar 18, 2024 · Past)
Board Member · Since at least May 27, 2026
Christopher Nixon Cox
Other companies: High-Trend International Group (Director · Since at least Mar 7, 2026); Newsmax, Inc. (Director · Since at least Mar 28, 2025)
Board Member · Since at least Feb 1, 2024
Maha Radhakrishnan
Other companies: Candel Therapeutics, Inc. (Director · Since at least Jun 4, 2025); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Jun 1, 2025)
Director · Mar 8, 2024 – Mar 8, 2024 · Past
Ramiro Sanchez
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Cerevel Therapeutics Holdings Inc (Chief Medical Officer · Oct 27, 2020 – Aug 1, 2024 · Past)
Director · Since at least Aug 12, 2025
Andrew Dreyfus
Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Apr 6, 2016)
Board Member · Since at least Feb 1, 2024
Michael Conick Hanley Jr
Other companies: Spyre Therapeutics, Inc. (Chief Business Officer · Oct 21, 2019 – Feb 23, 2023 · Past)
CHIEF OPERATING OFFICER · Since at least May 20, 2024
Adam SavitzChief Medical Officer · Since at least Feb 1, 2024
Amit EtkinFounder, President, and Chief Executive Officer · Since at least Feb 1, 2024
Erin R. McQuadeGeneral Counsel and Chief Administrative Officer · Since at least Nov 5, 2026
Gwill YorkDirector · Since at least Feb 1, 2024
All 17 people
PersonSeat
Husseini ManjiBoard Member · Since at least Feb 1, 2024
Jessica PowellChief Development Officer · Since at least Nov 5, 2026
Michael HanleyChief Operating Officer · Since at least Nov 5, 2026
Nicholas Conrad SmithPRESIDENT AND CFO · Since at least Feb 1, 2024
Nick SmithPresident and Chief Financial Officer · Since at least Aug 27, 2026
Po Yu ChenDirector · Feb 1, 2024 – Feb 6, 2024 · Past
Raymond SanchezBoard Member · Since at least Aug 13, 2025

Open People

Log in to ask 6ix AI your own questions about Alto Neuroscience, Inc.